title: Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics.
abstract: OBJECTIVE
  To evaluate the effectiveness and tolerance of vaginal cabergoline in hyperprolactinemic patients intolerant to oral dopaminergics.
  
  
  METHODS
  Case reports.
  
  
  METHODS
  University hospital endocrinological outpatient clinic.
  
  
  METHODS
  A 35-year-old primipara woman with idiopathic hyperprolactinemia and a 22-year-old female with primary amenorrhea harboring macroprolactinoma.
  
  
  METHODS
  Treatment with vaginal cabergoline (0.5 mg two and five times a week).
  
  
  METHODS
  The serum PRL levels and side effects were assessed before and during treatment.
  
  
  RESULTS
  A single vaginal dose of 0.5 mg cabergoline reduced serum PRL levels by approximately 50% to 85% of basal values over a period of 4 to 5 hours. In the patients with idiopathic hyperprolactinemia, serum PRL levels normalized during long-term treatment, whereas in the one with macroprolactinoma they remained above the normal values (79 ng/mL [conversion factor to SI unit, 3.180]) despite resumption of menses and marked tumor shrinkage (70% reduction). No side effects were reported.
  
  
  CONCLUSIONS
  Vaginal cabergoline is a safe and effective method of therapy for hyperprolactinemia and it avoids the adverse events of oral administration.
authors.affiliation: Prima Clinica Ostetrica e Ginecologica, Università di Milano, Italy.
authors.forename: T
authors.initials: T
authors.lastname: Motta
authors.forename: S
authors.initials: S
authors.lastname: de Vincentiis
authors.forename: M
authors.initials: M
authors.lastname: Marchini
authors.forename: N
authors.initials: N
authors.lastname: Colombo
authors.forename: A
authors.initials: A
authors.lastname: D'Alberton
mesh_terms: D000328:Adult; D001971:Bromocriptine / Q000009:adverse effects; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy*; D014621:Vagina
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D001971:Bromocriptine; D000077465:Cabergoline